Global biodiversity: indicators of recent declines
In 2002, world leaders committed, through the Convention on Biological Diversity, to achieve
a significant reduction in the rate of biodiversity loss by 2010. We compiled 31 indicators to …
a significant reduction in the rate of biodiversity loss by 2010. We compiled 31 indicators to …
Vitamin D, nervous system and aging
P Tuohimaa, T Keisala, A Minasyan, J Cachat… - …, 2009 - Elsevier
This is a mini-review of vitamin D 3 , its active metabolites and their functioning in the central
nervous system (CNS), especially in relation to nervous system pathologies and aging. The …
nervous system (CNS), especially in relation to nervous system pathologies and aging. The …
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
…, B Comin-Anduix, PC Tumeh, A Minasyan… - Cancer research, 2012 - AACR
Combining immunotherapy with targeted therapy blocking oncogenic BRAF V600 may
result in improved treatments for advanced melanoma. In this study, we developed a BRAF …
result in improved treatments for advanced melanoma. In this study, we developed a BRAF …
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, R Mallory, AVA Mendes, EP Milan, AM Minassian… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[PDF][PDF] Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and
responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that …
responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that …
[HTML][HTML] Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
…, DF McAuley, A Meyrick, AM Minassian… - … England Journal of …, 2021 - Mass Medical Soc
Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
The vitamin D neuroendocrine system as a target for novel neurotropic drugs
AV Kalueff, A Minasyan, T Keisala… - CNS & Neurological …, 2006 - ingentaconnect.com
Vitamin D is a seco-steroid hormone with multiple functions in the nervous system. Physiological
brain mechanisms of vitamin D and its receptors include neuroprotection, antiepileptic …
brain mechanisms of vitamin D and its receptors include neuroprotection, antiepileptic …
The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited
…, DS Janowsky, B Olivier, A Minassian… - European journal of …, 2015 - Elsevier
Bipolar disorder is a unique illness characterized by fluctuations between mood states of
depression and mania. Originally, an adrenergic–cholinergic balance hypothesis was …
depression and mania. Originally, an adrenergic–cholinergic balance hypothesis was …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, RP Marshall, AVA Mendes, EP Milan, AM Minassian… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
…, V Libri, MJ Llewelyn, AC McGregor, AM Minassian… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …